Is there breast implant-associated cancer (BIA-ALCL)?

Last Updated on

January 09, 2019 – Women should be alerted: Is there a thing like breast implant associated cancer (BIA-ALCL)? Yes, there is. Not every woman with a breast implant will get it, however. In fact, BIA-ALCL seems to be a rather rare condition; unfortunately, there is not yet a possibility to know prospectively who are the unlucky women who will be affected.

Most cases of breast implant-associated ALCL (BIA-ALCL) occur in women with textured breast implants.

BIA-ALCL is a rare cancer of the immune system. It is not breast cancer, which forms from cells in the breast, but instead a cancer that grows in the fluid and scar tissue that forms around a breast implant. The most common symptom of breast implant associated cancer is swelling of a breast caused by fluid build-up, but in some cases it may appear as a lump in the breast or armpit.

BIA-ALCL  will not be detected by a mammogram, and is usually tested for by analysis of a sample of the fluid around the implant. If you develop swelling of an implanted breast, your doctor will send you for an ultrasound scan to see if this is due to a fluid collection. If the ultrasound shows that fluid is present, a sample of the fluid will be removed and sent to a laboratory for analysis. Most fluid build-ups are not due to ALCL, but the laboratory test will be able to tell for sure.

 Most reported cases of BIA-ALCL  involve patients who have had a textured implant inserted at some point in their life. Patients with smooth implants may still develop this cancer if they have previously had a textured implant or tissue expander inserted. Based on current evidence, experts do not think BIA-ALCL  is related to either the contents (saline/silicone) or shape (round/teardrop) of the implant. However, BIA-ALCL  does occur at far higher rates among women with textured rather than smooth-surfaced implants. Thasso post had already a post on the possible price, the beauty of women has to pay on breast implants of this kind.

Noteworthy, there have been more than 600 cases of BIA-ALCL reported worldwide. In a very recent development, in December 2018 France’s National Agency for the Safety of Medicines and Health Products (ANSM) announced that Allergan’s textured breast implants can no longer be marketed in France and elsewhere in Europe (thasso post reported on it). Thus, according to ANSM, Allergan, one of the world’s largest manufacturers of breast implants, has been unable to renew safety certificates, known as CE marks, for two of its textured surfaces, namely Microcell and Biocell, used in products such as its Natrelle range of breast implants. According to EU-regulations, breast implants, like all medical devices, must have CE marks in order to be sold in 33 European countries. This loss of Allergan’s certificates comes after French regulators at ANSM last month recommended smooth-shell breast implants be used instead of textured-shell products, referring to links between the latter and anaplastic large cell lymphoma (i.e., BIA-ALCL) which in turn would impact on the health aspect for the CE registration of the textured breast implants (considered medical devices) in question.

Also the American Food and Drug Administration (FDA) is tracking the relationship between textured breast implants and breast implant-associated ALCL (BIA-ALCL).  According to their data base, breast implants, regardless of surface texture, are associated with a small risk of BIA-ALCL.  There appear to be multiple factors involved in the development of BIA-ALCL such as patient characteristics, operative procedure history, breast implant characteristics, including surface characteristics, and duration the breast implant is, or has been, in place. FDA will in due time inform about their findings too. It will be interesting to see, if a higher incidence of BIA-ALCL in woman whit textured breast implants. It would also be most interesting to find prospective firm risk factors (biomarkers, genetic predispositions, etc.) which would put patients at the highest risk for the development of BIA-ALCL.

See here a discussion of aspects surrounding BIA-ALCL:

Print Friendly, PDF & Email

Tags: , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Genetics may help predict the right blood pressure drug for you June 25, 2019
    Medication can play a huge role in reducing high blood pressure, a leading cause of stroke, heart attack and other serious health problems. Yet given the wide selection of drugs for doctors to choose from, figuring out which drug works best for someone is difficult.
  • First in vivo proof-of-concept in Steinert's myotonic dystrophy June 25, 2019
    Ana Buj Bello's team, a researcher in an Inserm unit at Genethon, the AFM-Telethon laboratory, has made the proof-of-concept of a CRISPR-Cas9 approach in a mouse model of Steinert's myotonic dystrophy, the most common neuromuscular disease in adults. Indeed, thanks to this genome editing approach, the expanded CTG triplet repeat in the DMPK gene, which […]
  • Gene networks reveal transition from healthy to failing heart June 24, 2019
    Scientists investigating heart failure have been limited to studying diseased heart tissue in the lab—understandably, as people don't tend to pluck out a healthy heart for the sake of research. But now, scientists with access to unusable, yet still healthy, donor hearts have been able to investigate the genomic pillars behind the transition from healthy […]
  • Microbiome links diet to health June 24, 2019
    The composition of the human microbiome, a complex ecosystem of microorganisms, plays a crucial role in lifelong health. Little is known, however, about the detailed molecular mechanisms linking health status to the microbiome of the gut, for example.
  • Researchers find new mutation in the leptin gene June 21, 2019
    The global obesity epidemic is so far-reaching it now has an overarching name: globesity. Texas Biomed Staff Scientist Raul Bastarrachea, M.D., is part of a team that discovered a new mutation in the gene that regulates the key hormone suppressing hunger called leptin. This new mutation could help researchers understand why people develop excess of […]
Top